AXSM vs NRXP
AXSM: A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel candidates. NRXP: Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three candidates in late-stage FDA review.
Side-by-side fundamentals
| Metric | AXSM | NRXP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $239.62 | $4.48 | |
| Market cap as of 2026-07-23 | $12.3B | $186M | |
| PEG as of 2026-07-23 | 2.51 | n/a | |
| Net margin as of 2026-07-23 | -26.6% | -2336.5% | AXSM higher |
| Gross margin as of 2026-07-23 | +92.6% | +58.8% | AXSM higher |
| Operating margin as of 2026-07-23 | -25.9% | -1830.6% | AXSM higher |
| ROE as of 2026-07-23 | -260.0% | -195.8% | NRXP higher |
| ROA as of 2026-07-23 | -27.8% | -219.6% | AXSM higher |
| Debt / equity as of 2026-07-23 | 3.61 | 1.42 | NRXP lower |
| Revenue growth (YoY) as of 2026-07-23 | +63.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +133.7% | n/a | |
| Beta as of 2026-07-23 | 0.73 | 2.14 | |
| 1-year return as of 2026-07-22 close | +116.0% | +49.8% | AXSM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.